Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong are investigating the Board of Directors of Juno Therapeutics, Inc. (NASDAQ: JUNO) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Celgene Corporation (NASDAQGS: CELG). Under the terms of the deal, Juno shareholders will receive $87 for each Juno share they own. The investigation concerns whether the Juno Board of Directors breached their fiduciary duties to Juno stockholders by failing to adequa...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Juno Therapeutics, Inc. (“Juno Therapeutics” or the “Company”) (NASDAQ:JUNO) stock prior to January 22, 2018. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Juno Therapeutics to Celgene Corporation (NASDAGS: CELG) for $87 per share. To learn more about the action and your rights, go to: http://www.zlk...
DALLAS--(BUSINESS WIRE)-- Former United States Securities and Exchange Commission attorney Willie Briscoe is investigating potential claims against the Board of Directors of Juno Therapeutics, Inc. (“Juno”) (NASDAQ: JUNO) concerning the acquisition by Celgene Corporation. Under the terms of the agreement, Juno shareholders will only receive $87.00 per Juno share owned. The consideration is significantly lower than at least one analyst’s estimated value of $98.00. If you are an affected investor, and you want to learn more abo...
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Juno Therapeutics, Inc. (NASDAQ GS: JUNO)? Did you purchase any of your shares prior to January 22, 2018? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Juno Therapeutics, Inc. (“Juno” or the “Company”) (NASDAQ GS: JUNO) ...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Juno Therapeutics, Inc. (“Juno Therapeutics” or the “Company”) (NASDAQ:JUNO) stock prior to January 22, 2018. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Juno Therapeutics to Celgene Corporation (NASDAGS:CELG) for $87 per share. To learn more about the action and your rights, go to: http://www.zlk....
NEW ORLEANS--(BUSINESS WIRE)-- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Juno Therapeutics, Inc. (NasdaqGS: JUNO). On June 14, 2017, a federal court refused to dismiss a securities fraud class action against Juno and certain of its executives, which was based on the Company’s failure to disclose material information regarding the true safety and efficacy of its leading immunotherapy drug ...
A director at Juno Therapeutics Inc sold after exercising options/sold 270,250 shares at 46.174USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's ...
NEW ORLEANS--(BUSINESS WIRE)-- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Juno Therapeutics, Inc. (NasdaqGS: JUNO). On June 14, 2017, a federal court refused to dismiss a securities fraud class action against Juno and certain of its executives, which was based on the Company’s failure to disclose material information regarding the true safety and efficacy of its leading immunotherapy drug ...
SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the appointment of Cindy Elkins as Chief Information Officer (CIO). Elkins will report to Hans Bishop, Juno’s President and CEO. “Cindy is a leader with a track record of increasing the impact of information technology in the biotech industry, focusing on innovation and delivering advanced technologies that support the discovery of bre...
SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced that it will webcast its presentation at the 36th Annual J.P. Morgan Healthcare Conference at 4:00 p.m. PT on Tuesday, January 9, 2018. The presentation will feature a business overview and update by Hans Bishop, Juno’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Juno's website at www.JunoTherapeutics.com. A replay of the presentation will be available at the same location for 30 ...
SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today highlighted presentations and data from the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia, December 9-12, 2017. “Juno presented a wide range of data and new insights at ASH, including updated data in the TRANSCEND trial,” said Hans Bishop, Juno’s President and CEO. “Using a defined composition of cells at a...
SEATTLE & SUMMIT, N.J.--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, and Celgene Corporation (NASDAQ: CELG) today released additional data from the TRANSCEND study of JCAR017 (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (NHL) in a presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition. This press release feat...
SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today presented new translational insights on clinical outcomes with its investigational CAR T product candidate JCAR017 at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition. Juno also announced that JCAR017, a defined composition CD19-directed CAR T cell product candidate using a 4-1BB costimulatory domain, had received the United S...
SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced three license agreements to advance its program in multiple myeloma using gamma secretase inhibitors (GSIs) in combination with BCMA-directed CAR T cells. Gamma secretase is an enzyme that cleaves a set of transmembrane proteins, including BCMA. Multiple publications have shown that treatment with GSIs can increase surface expression of BCMA ...
SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the appointment of Ann L. Lee, Ph.D., as Executive Vice President of Technical Operations. Dr. Patrick Y. Yang will assume the role of Executive Vice President, Senior Advisor to the CEO. Both will report to Hans Bishop, President and CEO, and work to further advance Juno as a global leader in T cell engineering and manufacturing. In h...
SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in November. The presentations will feature a business overview and update by Steve Harr, Juno’s Chief Financial Officer and Head of Corporate Development. Juno will present at the 26th Annual Credit Suisse Healthcare Conference at 9:15 a.m. Mountain Time (MT) on Wednesday, November 8, 2017. Juno will present at the Evercore ISI Biopharma Catalyst / De...
SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today reported financial results and business highlights for the third quarter 2017. "We are pleased with the potential best-in-class profile for JCAR017, and we look forward to presenting an updated dataset at the upcoming ASH conference," said Hans Bishop, Juno’s President and Chief Executive Officer. "The clinical data continue to support our belief that ...
SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that 15 abstracts detailing updated clinical and preclinical results from the company and its collaborators will be presented at the 59th American Society of Hematology (ASH) Annual Meeting. Senior executives will also review results and provide an update on Juno’s clinical development program at an analyst and investor event, which will also be avail...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.